Legacy Education Inc. (LGCY) - Q1 2025 (Ended Sept 30, 2024) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended September 30, 2024 (Q1 Fiscal 2025). Legacy Education Inc. operates three accredited career colleges in California: High Desert Medical College, Central Coast College, and Integrity College of Health. The company focuses on healthcare, veterinary, and business management training. During this period, the company completed its Initial Public Offering (IPO) and executed a 1-for-2 reverse stock split.
Key Financial Metrics
| Metric | Q1 2025 (Sep 30, 2024) | Q1 2024 (Sep 30, 2023) |
|---|---|---|
| Revenue | $14,005,091 | $10,366,934 |
| Net Income | $2,090,753 | $1,069,596 |
| Operating Income | $2,672,276 | $1,380,544 |
| Operating Margin | 19.1% | 13.3% |
| Net Cash from Operations | $3,185,254 | $484,617 |
| Cash & Equivalents (Ending) | $21,492,618 | $9,491,107 |
| Total Debt (Current + Long-term) | $758,172 | Filing text does not provide clear total for 2023 |
| EPS (Diluted) | $0.21 | $0.11 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 35.1% year-over-year, driven by a 25.4% increase in total enrollment (from 2,024 to 2,539 students) and a favorable shift in program mix toward higher-earning programs.
- Profitability: Net income nearly doubled (95.5% increase) due to revenue growth outpacing expense increases. Operating margins expanded from 13.3% to 19.1%.
- Liquidity Event: The company completed its IPO on September 27, 2024, issuing 2,500,000 shares at $4.00 per share. Net proceeds were approximately $7.9 million. Subsequent to the period end, an additional 375,000 shares were issued via the underwriters' over-allotment option.
- Expense Trends: Educational services expenses rose 25.7% to support higher enrollment. General and administrative expenses increased 25.7%, primarily due to higher marketing spend ($1.2M vs $1.1M) and professional fees.
Outlook, Risks, and Contingencies
- Acquisition Activity: On October 22, 2024, the company entered an agreement to acquire Contra Costa Medical Career College for $8.0 million (cash, promissory note, and stock). The transaction is subject to regulatory approvals, including a change of control review by the U.S. Department of Education (ED).
- Regulatory Risks: The company is heavily reliant on Title IV federal student aid. It must maintain a composite score of at least 1.5 (current score 3.0) and comply with the 90/10 revenue rule (Title IV funds cannot exceed 90% of revenue). The 90/10 calculation for FY2024 is pending.
- Forward-Looking Statements: Management notes risks related to regulatory investigations, enrollment declines, and the ability to maintain accreditation. The company is an "Emerging Growth Company" under the JOBS Act.
Investor Verification Checklist
- Enrollment Quality: Verify the sustainability of the 25% enrollment increase and the specific mix of high-margin programs driving revenue.
- Regulatory Compliance: Confirm the status of the 90/10 revenue test for the fiscal year ended June 30, 2024, and the outcome of the ED change-of-control review for the Contra Costa acquisition.
- Use of Proceeds: Monitor the deployment of the ~$9.3 million in total IPO proceeds (including over-allotment) against the planned acquisition and operational expansion.
- Debt Structure: Review the terms of the $758k total debt, including the related-party promissory notes and equipment loans, to assess near-term cash flow obligations.